Structure Therapeutics (GPCR) Net Equity Issued and Repurchased (2025)

Structure Therapeutics' (GPCR) quarterly Net Equity Issued and Repurchased came in at $57.1 million in Q3 2025.

Structure Therapeutics (GPCR) Net Equity Issued and Repurchased (2025) Analysis & Trends

Structure Therapeutics' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $57.1 million for Q3 2025.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $57.1 million in Q3 2025; TTM through Sep 2025 was $57.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $57.1 million, down 88.91% from the prior year.
  • Net Equity Issued and Repurchased was little changed at $57.1 million in Q3 2025 per GPCR's latest filing.
  • Across five years, Net Equity Issued and Repurchased topped out at $57.1 million in Q3 2025 and bottomed at $57.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Structure Therapeutics 11.04 Bn 11.04 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 57.10 Mn
Sep 30, 2025 57.10 Mn